» Articles » PMID: 33112988

State-of-the-Art Glycomics Technologies in Glycobiotechnology

Overview
Date 2020 Oct 28
PMID 33112988
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Glycosylation affects the properties of biologics; thus regulatory bodies classified it as critical quality attribute and force biopharma industry to capture and control it throughout all phases, from R&D till end of product lifetime. The shift from originators to biosimilars further increases importance and extent of glycoanalysis, which thus increases the need for technology platforms enabling reliable high-throughput and in-depth glycan analysis. In this chapter, we will first summarize on established glycoanalytical methods based on liquid chromatography focusing on hydrophilic interaction chromatography, capillary electrophoresis focusing on multiplexed capillary gel electrophoresis, and mass spectrometry focusing on matrix-assisted laser desorption; we will then highlight two emerging technologies based on porous graphitized carbon liquid chromatography and on ion-mobility mass spectrometry as both are highly promising tools to deliver an additional level of information for in-depth glycan analysis; additionally we elaborate on the advantages and challenges of different glycoanalytical technologies and their complementarity; finally, we briefly review applications thereof to biopharmaceutical products. This chapter provides an overview of current state-of-the-art analytical approaches for glycan characterization of biopharmaceuticals that can be employed to capture glycoprotein heterogeneity in a biopharmaceutical context.

Citing Articles

Developments and perspectives in high-throughput protein glycomics: enabling the analysis of thousands of samples.

de Haan N, Pucic-Bakovic M, Novokmet M, Falck D, Lageveen-Kammeijer G, Razdorov G Glycobiology. 2022; 32(8):651-663.

PMID: 35452121 PMC: 9280525. DOI: 10.1093/glycob/cwac026.


Bisecting Lewis X in Hybrid-Type -Glycans of Human Brain Revealed by Deep Structural Glycomics.

Helm J, Grunwald-Gruber C, Thader A, Urteil J, Fuhrer J, Stenitzer D Anal Chem. 2021; 93(45):15175-15182.

PMID: 34723506 PMC: 8600501. DOI: 10.1021/acs.analchem.1c03793.


A spoonful of L-fucose-an efficient therapy for GFUS-CDG, a new glycosylation disorder.

Feichtinger R, Hullen A, Koller A, Kotzot D, Grote V, Rapp E EMBO Mol Med. 2021; 13(9):e14332.

PMID: 34468083 PMC: 8422078. DOI: 10.15252/emmm.202114332.


Combining functional metagenomics and glycoanalytics to identify enzymes that facilitate structural characterization of sulfated N-glycans.

Chuzel L, Fossa S, Boisvert M, Cajic S, Hennig R, Ganatra M Microb Cell Fact. 2021; 20(1):162.

PMID: 34419057 PMC: 8379841. DOI: 10.1186/s12934-021-01652-w.

References
1.
Butler M, Spearman M . The choice of mammalian cell host and possibilities for glycosylation engineering. Curr Opin Biotechnol. 2014; 30:107-12. DOI: 10.1016/j.copbio.2014.06.010. View

2.
York I, Stevens J, Alymova I . Influenza virus N-linked glycosylation and innate immunity. Biosci Rep. 2018; 39(1). PMC: 6328934. DOI: 10.1042/BSR20171505. View

3.
Newburg D, Grave G . Recent advances in human milk glycobiology. Pediatr Res. 2014; 75(5):675-9. PMC: 4125201. DOI: 10.1038/pr.2014.24. View

4.
Yu Z, Chen C, Kling D, Liu B, McCoy J, Merighi M . The principal fucosylated oligosaccharides of human milk exhibit prebiotic properties on cultured infant microbiota. Glycobiology. 2012; 23(2):169-77. PMC: 3531294. DOI: 10.1093/glycob/cws138. View

5.
Liu B, Newburg D . Human milk glycoproteins protect infants against human pathogens. Breastfeed Med. 2013; 8(4):354-62. PMC: 3725943. DOI: 10.1089/bfm.2013.0016. View